Form SCHEDULE 13D/A Regencell Bioscience Filed by: Regencell (BVI) Ltd

July 11, 2025 4:15 PM EDT





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
The information had reflected the effect of the Issuer's 38-for-one forward stock split paid in the form of a stock bonus on June 13, 2025 (the "Forward Stock Split").


SCHEDULE 13D




Comment for Type of Reporting Person:
The information had reflected the effect of the Forward Stock Split.


SCHEDULE 13D


 
Regencell (BVI) Limited
 
Signature:/s/ Yat-Gai Au
Name/Title:Yat-Gai Au, Sole Director
Date:07/11/2025
 
Yat-Gai Au
 
Signature:/s/ Yat-Gai Au
Name/Title:Yat-Gai Au
Date:07/11/2025


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings

Related Entities

13D